Clinical Trial Update: Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab combined with irinotecan in pediatric patients with recurrent or progressive brain tumors including gliomas, medulloblastom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brainstem Glioma
• Cerebral Anaplastic Astrocytoma
• Ependymoma
• Medulloblastoma
• Oligodendroglioma
• Spinal Cord Neoplasm

Drugs mentioned

• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma | Phase 2 | Status: COMPLETED | Results posted: 2013-01-15